Also found in: Thesaurus, Medical, Acronyms, Wikipedia.
Related to infliximab: methotrexate


A chimeric monoclonal antibody that blocks the action of tumor necrosis factor and is used to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, and certain other inflammatory conditions.

[Perhaps inf(lammatory) + -li-, immunomodulator infix + -ximab (as in rituximab).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.infliximab - a monoclonal antibody (trade name Remicade) used to treat Crohn's disease and rheumatoid arthritis; administered by infusion; use and dosage must be determined by a physician
monoclonal, monoclonal antibody - any of a class of antibodies produced in the laboratory by a single clone of cells or a cell line and consisting of identical antibody molecules
2.infliximab - an anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF; it is given intravenously at one-month to three-month intervals; used in treatment of regional enteritis and rheumatoid arthritis
anti-TNF compound - a class of drugs that block the action of tumor necrosis factor (TNF); used in cases of rheumatoid arthritis because TNF instigates inflammation of the joints
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


n infliximab m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
- The European Medicines Agency has accepted for review of the Extension Marketing Authorisation Application for 'Remsima SC', the subcutaneous version of Remsima, the autoimmune disease therapeutic antibody biosimilar of infliximab, South Korean biopharmaceutical company Celltrion, Inc.
Biosimiiar drugs offer the prospect of alternatives that are more cost-effective than their original versions (known as reference drugs).To distinguish them from their reference drugs, biosimilars must be given different generic names--so, for example, instead of the biological response modifier infliximab (Remicade), a person with RA may be prescribed its biosimiiar versions: infliximab-dyyb (Inflectra) or infliximab-abda (Renflexis).
5, 2018 (HealthDay News) -- Under Medicare Part D, out-of-pocket costs are similar for infliximab and its biosimilar infliximab-dyyb, according to a research letter published in the Sept.
AMONG PSORIASIS PATIENTS, treatment with infliximab was associated with an increased risk of serious infections that led to hospitalization, the use of intravenous antimicrobial therapy, or death, according to a prospective cohort study of cases in the United Kingdom and the Republic of Ireland.
The results confirm non-inferiority compared to infliximab but could not rule out superiority based on its primary efficacy endpoint, which compared the response difference measured by 20% or greater improvement defined by the American College of Rheumatology Criteria, ACR20, at week 22.
It was reported on Friday that the European Commission has approved Germany-based Sandoz's Zessly (infliximab) for the treatment of gastroenterological, rheumatological and dermatological diseases.
At symptom onset, she had received infliximab and azathioprine for >5 years and reported eating undercooked meat; she had not traveled abroad.
and Biocon Ltd.'s Ogivri (trastuzumabdkst), a biosimilar to Herceptin (trastuzumab) from Genentech Inc., and Pfizer Inc.'s Ixifi (infliximab-qbtx), a biosimilar to Remicade (infliximab) from Janssen Biotech Inc.
In a statement the CMA said: "The CMA has provisionally found that MSD broke competition law by abusing its dominant position through a discount scheme for Remicade that was likely to restrict competition from 'biosimilar' versions of infliximab that were new to the market.
Amherst, NH, May 02, 2017 --( BUHLMANN Diagnostics Corp (BDC), BUHLMANN Laboratories AG's North American affiliate is proud to announce that three of its novel products, Quantum Blue[R] Infliximab Assay, IBDoc[R] and CALEX[R] Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada.
The FDA has approved Samsung Bioepis' Renflexis (infliximab-abda), a biosimilar referencing Remicade (infliximab), across all eligible indications.